Added to YB: 2026-04-27
Pitch date: 2026-04-23
ACTU [bullish]
Actuate Therapeutics, Inc.
-23.23%
current return
Author Info
No bio for this author
Company Info
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States.
Market Cap
$68.5M
Pitch Price
$2.54
Price Target
12.75 (+534%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-2.73
EV/Sales
N/A
Sector
Biotechnology
Category
growth
ACTU — Actuate Therapeutics, $2.59
ACTU: Randomized Phase 2 in metastatic pancreatic cancer published in Nature Medicine showed elraglusib + chemo doubled 1yr survival (44.1% vs 22.3%), median OS 10.1 vs 7.2mo, 38% death risk reduction. Exploratory data showed 7-40x immune cell infiltration. M&A score 82 on rare PDAC survival benefit, combo-ready with RAS/IO, $54M mcap. HC Wainwright $12.75 PT. Risks: Phase 3 needed, single asset, dilution.
Read full article (2 min)